Fondazione FORT

La Fondazione Ricerca Traslazionale (FoRT), si propone di svolgere attività scientifica e di ricerca nel settore biomedico con particolare, ma non esclusivo, interesse alla ricerca traslazionale applicata in campo oncologico, pre-clinico e clinico.

Studio clinico PFROST

"PF‐06463922 for crizotinib pretreated ROS1 positive nonsmall‐cell lung cancer: a phase II Trial (PFROST)"

Studio clinico METROS

"Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or MET exon 14 mutation or ROS1 translocation (METROS)"

Studio clinico SQUINT

"An openlabel, randomized, phase II trial of nivolumab plus ipilimumab versus platinumbased chemotherapy in chemonaive metastatic or recurrent Squamous-Cell Lung Cancer (SqLC)"

Studio clinico FLIBER

"Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC)"

Studio clinico CABinMET

"Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation"

Studio clinico SPECIALK

"Crizotinib in ALK rearranged non-small-cell lung cancer: a retrospective study"

BEAT

"Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1+ advanced non-small-cell lung cancer patients"

STARDUST

"Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non-Small-Cell Lung Cancer patients receiving concomitant steroids"

Studio clinico BIO-COLLECT

"Database patologie polmonari"

CHIUDI X
 
CHIUDI X
 
CHIUDI X
 
Helpdesk:
Mail: info@cr-technology.com
Tel. 089/301545 - Fax. 089/7724155
Dal lunedí al venerdí: 10:00-13:00 e 15:00-18:00